免責事項: 本サイトは、FDA、ClinicalTrials.gov、PubMed、SEC EDGAR などの公式公開データを一般参考用に集約するものであり、医学的助言、診断、治療推奨、投資助言を構成しません。

PubMed

前立腺の焦点高強度集束超音波消融(Focal High-Intensity Focused Ultrasound Ablation of the Prostate)

PMID: 34499554 · 2021

L, a, u, r, e, n, , R, , A, b, r, a, m, s, ;, , M, i, c, h, a, e, l, , O, , K, o, c, h, ;, , C, l, i, n, t, o, n, , D, , B, a, h, l, e, r

学術誌Journal of endourology
年2021
PMID34499554

抄録

With the advancement of early detection tools for prostate cancer and ability to better localize disease, there has been increased interest in focal or targeted therapies that carry less morbidity than traditional whole-gland treatments. The Sonablate® high-intensity focused ultrasound (HIFU) device has Food and Drug Administration (FDA) 510(K) clearance in the United States for ablation of prostate tissue. HIFU utilizes an ultrasound (US) transducer that focuses US beams on a preset point as mu

公式ソース

PubMedで見る →

データはPubMed / NCBIから取得しています。全文および最新情報は必ず公式記録をご確認ください。

↑